Pennsylvania PACE Predicts Crisis From Medicare HMOs Dropping Rx Benefits
Executive Summary
Pennsylvania's Pharmaceutical Assistance Contract for the Elderly will face a crisis in the upcoming year because it will have to pick up patients who leave Medicare HMOs, PACE Director Thomas Snedden told the Generic Pharmaceutical Industry Association March 27 in New York City.
You may also be interested in...
Par 7.5 Mg Buspirone Aims To Capture Portion of 15 Mg Split-Tablet Market
Par Pharmaceutical hopes to capture a portion of the 15 mg buspirone market with the March 28 approval of its 7.5 mg strength of the anxiety drug buspirone, a generic equivalent of Bristol-Myers Squibb's BuSpar. Par has 180-day exclusivity for 7.5 mg buspirone.
Pennsylvania PACE legislation proposes differential co-pay for generics.
PENNSYLVANIA "PACENET" TO INCLUDE DIFFERENTIAL GENERIC CO-PAY as part of legislation proposed by Gov. Tom Ridge (R) to expand Pharmaceutical Assistance Contract for the Elderly benefits in the state. Ridge is proposing a new tier of eligibility, called PACENET, that would involve an $8 co-pay for generic drugs or a $15 co-pay for brands. The current PACE program calls for a $6 co-pay for all prescriptions. The bill is being sponsored by state Sen. David Heckler (R).
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011